<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TESTOLACTONE</span><br/>(tess-toe-lak'tone)<br/><span class="topboxtradename">Teslac<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">hormone</span>; <span class="classification">anabolic steroid</span><br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule III<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Chemotherapeutic agent with chemical configuration similar to certain androgens but devoid of androgenic activity (virilization)
         in therapeutic doses. Exact mechanism of antineoplastic action unknown.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In breast cancer, effect may result from depression of ovarian function by inhibition of synthesis of pituitary gonadotropin.
         Indicated by decrease in size of tumor; more than 50% of nonosseous lesions decrease in size even though all bone lesions
         remain static.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive treatment in palliation of breast carcinoma in postmenopausal women when hormone therapy is indicated. Also effective
         in women diagnosed before menopause in whom ovarian function has been subsequently terminated.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Premenopausal women; breast cancer in males. Pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypercalcemia; cardiorenal disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adjunctive Therapy for Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg q.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li> 				Note: If anticoagulants are concurrently ordered, dose is usually reduced when testolactone is initiated. 			</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed. Protect from freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Paresthesias. <span class="typehead">Endocrine:</span> Deepening of the voice, acne, facial hair growth, clitoral enlargement. <span class="typehead">GI:</span> Glossitis, anorexia; nausea, vomiting. <span class="typehead">CV:</span> Hypertension, edema in extremities. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p> <span class="alt">Urinary 17-OHCS</span> determinations may be elevated.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May enhance hypoprothrombinemic effects of <span class="classification">oral anticoagulants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness. Clinical response usually occurs in 612 wk.</li>
<li>Lab tests: Check plasma calcium levels periodically (normal serum calcium: 8.510.6 mg/dL).</li>
<li>Monitor PT and INR carefully with concurrent anticoagulant therapy.</li>
<li>Report S&amp;S that suggest impending hypercalcemia (see Appendix F).</li>
<li>Monitor I&amp;O ratio and pattern.</li>
<li>Encourage patient mobility if feasible; if not, assist with passive exercises.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Drug treatment is usually continued for a minimum of 3 mo to evaluate response (unless there is active progression of the
            disease).
         </li>
<li>Be aware that hypercalcemia represents active remission of bone metastasis; if it occurs, appropriate therapy is instituted.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>